BNT327 deal bolsters BioNTech’s competitive position, says Leerink

Leerink analyst Daina Graybosch reiterated an Outperform rating and $112 price target on BioNTech (BNTX), with the firm saying the company’s deal with Bristol Myers (BMY) is “highly positive” and believes there is continued upside for the stock as investors digest the value Bristol Myers brings to maximizing the value of BNT327. The firm expects less volatility to BioNTech from the COVID vaccine franchise, as the FDA and CDC’s regulatory actions are largely known, but does note the CDC’s Advisory Committee on Immunization Practices June 25-27 meeting has upside and downside potential.